Augmentation of ADCC and cytotoxic T-cell activity with ImuVert.
We previously reported that natural killer cell activity of peripheral blood mononuclear cells (PBMC) from healthy human subjects was augmented following in vitro incubation in ImuVert, a biologic response modifier derived from the bacterium Serratia marcescens. In the current investigation, we found that exposure of PBMC to ImuVert, 3-40 micrograms/ml, for 18 hr, resulted in significant and dose-dependent augmentation of three other types of cell-mediated cytotoxicity: K cell-mediated antibody-dependent cellular cytotoxicity (ADCC), monocyte-mediated ADCC, and cytotoxic T-cell activity against allogeneic PBMC. These and previous findings suggest that ImuVert may have a broad range of stimulatory effects on immune function.
Warren
R P
RP
Department of Biology, Utah State University, Logan 84322.
McCall
C A
CA
Urban
R W
RW
D000328:Adult; D000920:Antibody-Dependent Cell Cytotoxicity; D001688:Biological Products; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000276:immunology; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D001688:Biological Products; D007155:Immunologic Factors; C062792:ImuVert